活心丸联合伊伐布雷定治疗稳定型心绞痛的临床研究

目的 探讨活心丸联合盐酸伊伐布雷定片治疗稳定型心绞痛的临床疗效。方法 选取2021年4月—2023年5月来宾市兴宾区人民医院收治的102例稳定型心绞痛患者，按照随机数字表将患者分为对照组（51例）和治疗组（51例）。对照组口服盐酸伊伐布雷定片，1片/次，2次/d。治疗组在对照组基础上口服活心丸，2丸/次，2次/d。治疗8周分析治疗效果。比较两组的总有效率、心绞痛症状、冠状动脉血管狭窄程度和血清指标。结果 治疗后，治疗组的总有效率为94.12%，对照组的总有效率为80.39%，组间差异明显（P＜0.05）。治疗后，两组的心绞痛发作频率、疼痛持续时间、视觉模拟评分法（VAS）评分、Gensini评分均显著降低（P＜0.05）；治疗组的心绞痛发作频率、疼痛持续时间、VAS评分、Gensini评分低于对照组（P＜0.05）。治疗后，两组的血清氧化性低密度脂蛋白受体-1（LOX-1）、高迁移率族蛋白1（HMGB1）水平低于治疗前，血清可溶性晚期糖基化终末产物受体（SRAGE）水平高于治疗前（P＜0.05）；治疗组的血清LOX-1、HMGB1水平低于对照组，血清SRAGE水平高于对照组（P＜0.05）。结论 活心丸联合盐酸伊伐布雷定片可提高稳定型心绞痛的临床疗效，减轻心绞痛症状、冠状动脉狭窄程度和炎症反应。

Clinical study on Huoxin Pills combined with ivabradine in treatment of stable angina pectoris

Objective To investigate the clinical effect of Huoxin Pills combined with Ivabradine Hydrochloride Tablets in treatment of stable angina pectoris. Methods Patients (102 cases) with stable angina pectoris in Xingbin District People''s Hospital of Laibin City from April 2021 to May 2023 were divided into control and treatment groups according to the random number table method, with 51 cases in each group. Patients in the control group were po administered with Ivabradine Hydrochloride Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Huoxin Pills on the basis of the control group, 2 pills/time, twice daily. Therapeutic effect was evaluated after 8 weeks of treatment. The total effective rates, symptoms of angina pectoris, the degree of coronary stenosis, and the serum markers in two groups were compared. Results After treatment, the total effective rate of the treatment group was 94.12%, while the total effective rate of the control group was 80.39%, with a significant difference between the groups (P < 0.05). After treatment, the frequency of angina attacks, the duration of pain, VAS score, and Gensini score in two groups were significantly decreased (P < 0.05), and the frequency of angina attacks, the duration of pain, VAS score, and Gensini score in the treatment group were lower than those in the control group (P < 0.05). After treatment, the serum levels of LOX-1 and HMGB1 in two groups were lower than before treatment, but serum levels of SRAGE in two groups were higher than before treatment (P < 0.05). The serum levels of LOX-1 and HMGB1 in the treatment group were lower than those in the control group, but the serum levels of SRAGE in the treatment group were higher than those in the control group (P < 0.05). Conclusion Huoxin Pills combined with Ivabradine Hydrochloride Tablets can improve the clinical efficacy of stable angina, alleviate symptoms of angina, reduce the degree of coronary artery stenosis, and inflammatory response.